[1]黄泽海,王子明,陈杨,等.成纤维细胞生长因子受体抑制剂BGJ398对肾癌细胞生物学行为的影响[J].中华腔镜泌尿外科杂志(电子版),2017,11(04):277-282.[doi:10.3877/cma.j.issn.1674-3253.2017.04.015 ]
　Huang Zehai,Wang Ziming,Chen Yang,et al.The inhibitory effects of fibroblast growth factor receptor inhibitor BGJ398 on renal cell carcinoma[J].,2017,11(04):277-282.[doi:10.3877/cma.j.issn.1674-3253.2017.04.015 ]
点击复制

成纤维细胞生长因子受体抑制剂BGJ398对肾癌细胞生物学行为的影响()
分享到：

中华腔镜泌尿外科杂志(电子版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
11
期数:
2017年04期
页码:
277-282
栏目:
实验研究
出版日期:
2017-08-31

文章信息/Info

Title:
The inhibitory effects of fibroblast growth factor receptor inhibitor BGJ398 on renal cell carcinoma
作者:
黄泽海1; 王子明1; 2; 陈杨1; 2; 黄晓敏1; 陈彤1; 郑少斌1
510515 广州，南方医科大学南方医院泌尿外科1；510515 广州，南方医科大学2
Author(s):
Huang Zehai1;  Wang Ziming1; 2;  Chen Yang1; 2;  Hang Xiaomin1;  Chen Tong1;  Zheng Shaobin1.
1Department of Urology, Nanfang Hospital, Southern Medical University, 2Southern Medical University, Guangzhou 510515,China
关键词:
肾癌;  成纤维细胞生长因子;  抑制剂; 增殖;  侵袭力
DOI:
10.3877/cma.j.issn.1674-3253.2017.04.015
摘要:
目的 研究成纤维细胞生长因子（FGFR）抑制剂BGJ398 对人源肾癌细胞株OSRC-2 增殖、黏附及其对细胞侵袭功能的影响，为肾细胞癌的靶向治疗提供新思路。方法用不同浓度（0、0.1、0.5、1、2、5、10 μmol/L）的FGFR 抑制剂BGJ398 处理体外培养的人源肾癌细胞OSRC-2 后，通过CCK8 法检测细胞增殖变化；激光共聚焦显微镜观察BGJ398 对细胞的活力和骨架的影响；Transwell 小室法检测BGJ398 对人肾癌细胞侵袭能力的影响。结果 BGJ398 能明显抑制OSRC-2 细胞增殖。CCK8 结果显示BGJ398 处理人肾癌细胞后，细胞增殖受到抑制，并具有剂量依赖性。Live/Dead 荧光染色实验证明BGJ398 可显著抑制肾癌细胞的增殖及活力（P<0.01）。细胞黏附及Transwell 实验结果表明，BGJ398 可抑制细胞骨架的重塑及侵袭效应（P<0.01）。结论 BGJ398对肾癌细胞的增殖，活力和侵袭力具有明显的抑制作用。抑制FGFRs 有望成为肾癌治疗的新靶点，为FGFR 特异性抑制剂成为潜在的肾癌靶向治疗药物提供实验证据。

参考文献/References:

[1] Cheng W, Wu C, Qi Y, et al. miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B[J]. Oncotarget, 2016, 7(45):73888-73902.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China,2015[J]. Ca A Cancer Journal for Clinicians, 2016, 66(2):115-123.
[3] Guo M, Cao Y, Yang J, et al. A comparison of drug resistances of targeted drugs for advanced renal cell cancer approved by the Food and Drug Administration: A meta-analysis of randomized clinical trials[J]. J Cancer Res Ther, 2016,12(Supplement):109-115.
[4] Coleman SJ, Bruce C, Chioni AM, et al. The ins and outs of fibroblast growth factor receptor signalling[J]. Clin Sci (Lond ),2014,127(4):217-231.
[5] Masaru K. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review):[J]. Int J Mol Med, 2016, 38(1): 3-15.
[6] Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth[J]. Curr Cancer Drug Targets, 2009, 9(5):639-651.
[7] Dieci MV, Arnedos M, Andre F, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic raotniale to medical perspectives[J]. Cancer Discov, 3(3): 264-279.
[8] Wang QY, Zhao Y, Zhang R. The role of mutations and overexpression of the fibroblast growth factor receptor-3 in baldder cancer[J]. Minerva Med, 2015, 106(6):333-337.
[9] Jia YX, Li TF, Zhang DD, et al. The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric nccaer:a retrospective study[J]. Onco Targets Ther, 2016, 9:5919-5929.
[10] Ishiwata T, Matsuda Y, Yamamoto T, et al. Enhanced Expression of Fibroblast Growth Factor Receptor 2 IIIc Promotes Human Pancretaic Cancer Cell Proliferation[J]. Am J Pathol, 2012, 180(5):1928-1491.
[11] Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo[J]. Br J Cancer, 2011, 104(1):75-82.
[12] Criscitiello C, Esposito A, De PS, et al. Targeting fibroblasgtr owth factor receptor pathway in breast cancer[J]. Curr Opin Oncol, 2015,27(6):452-456.
[13] Thomson S, Petti F, Sujka-Kwok I, et al. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy[J]. Clin Exp Metastasis, 2008, 25(8):843-854.
[14] Feng S, Shao L, Yu W, et al. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression[J]. Clni Cancer Res, 2012, 18(14):3880-3888.
[15] Erbe AK, Wang W, Goldberg J, et al. FCGR Polymorphisms Influence Response to IL-2 in Metastatic Renal Cell Carcinoma[J].Clin Cancer Res, 2017, 23(9): 2159-2168.
[16] Zhang T, Zhu J, George DJ, et al. Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies[J]. Urol Oncol, 2016, 34(11): 510-518.
[17] Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fiobbrlast growth factor receptor inhibitors dovitinib (TKI258) and NVPBGJ398 in human endometrial cancer cells[J]. Mol Cancer Ther,2013, 12(5):632-642.
[18] Chen YS, Meng F, Li HL, et al. Dicer suppresses MMP-2-mediated invasion and VEGFA-induced angiogenesis and serves as a promising prognostic biomarker in human clear cell renal cell carcinoma[J].Oncotarget, 2016, 7(51): 84299-84313.
[19] López JI. Intratumor heterogeneity in clear cell renal cell carcinoma: a review for the practicing pathologist[J]. APMIS, 2016,124(3): 153-159.
[20] Mikami S, Oya M, Mizuno R, et al. Recent advances in renal cell carcinoma from a pathological point of view[J]. Pathol Int, 2061,66(9): 481-490.
[21] Tsimafeyeu I, Demidov L, Stepanova E, et al. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma[J]. Scand J Urol, 2011, 45(3):190-195.

相似文献/References:

[1]刘卓炜,周芳坚,韩辉,等.临床T1期肾癌后腹腔镜根治术的治疗报告[J].中华腔镜泌尿外科杂志(电子版),2007,(02):106.
　LIU Zhuo-wei,ZHOU Fang-jian,HAN Hui,et al.Laparoscopic radical nephrectomy for the treatment of clinic T1N0M0 renal cell carcinoma[J].,2007,(04):106.
[2]王晓庆,汪岩,卢绩,等.后腹腔镜与开放肾癌根治性手术的回顾性比较[J].中华腔镜泌尿外科杂志(电子版),2008,(04):5.
　WANG Xiao-qing,WANG Yan,LU Ji,et al.Retrospective comparison of retroperitoneoscopic versus open radical nephrectomy for renal carcinoma[J].,2008,(04):5.
[3]张亚琴,方友强,沈敏,等.磁共振在小肾癌诊断中的应用[J].中华腔镜泌尿外科杂志(电子版),2009,(01):51.
　ZHANG Ya-qin,FANG You-qian,Shen Min,et al.Evaluation of small renal carcinoma with MRI[J].,2009,(04):51.
[4]刘隆忠,裴小青,郑玮,等.超声造影技术在肾癌诊断中的临床应用价值[J].中华腔镜泌尿外科杂志(电子版),2011,(05):361.
　LIU Long-zhong,PEI Xiao-qing,ZHEN Wei,et al.Evaluation of renal carcinoma with contrast-enhanced ultrasound[J].,2011,(04):361.
[5]李前跃,王砺,李志坤,等.后腹腔镜下肾癌根治术65例临床疗效分析[J].中华腔镜泌尿外科杂志(电子版),2012,(01):17.
　LI Qian-yue,WANG Li,LI Zhi-kun,et al.Retroperitoneal laparoscopic radical nephrectomy for renal cell carcinoma: Report of 65 cases[J].,2012,(04):17.
[6]毕良宽,周楠,刘成,等.肾癌中Card9的表达及作用机制研究[J].中华腔镜泌尿外科杂志(电子版),2013,(05):58.
[7]蔡松旺 廖洪映 安军 黄邵洪 翁毅敏 李昀 何锦园 张军航 狄金明.肾区手术史的腹腔镜肾癌根治术后气胸的诊治[J].中华腔镜泌尿外科杂志(电子版),2014,(06):441.[doi:10.3877/cma.j.issn.1674-3253.2014.06.011 ]
　Cai Songwang*,Liao Hongying,An Jun,et al.Mechanism and preventive measures of pneumothorax in laparoscopic radical nephrectomy with a history of retroperitoneal operation[J].,2014,(04):441.[doi:10.3877/cma.j.issn.1674-3253.2014.06.011 ]
[8]戴志红,刘志宇.囊性肾癌肾部分切除术的实践与思考[J].中华腔镜泌尿外科杂志(电子版),2023,17(04):422.
　[J].,2023,17(04):422.
[9]刘茁.【视频讲座】北医三院肾癌伴随下腔静脉癌栓分级系统和临床特色研究[J].中华腔镜泌尿外科杂志(电子版),2023,17(04):423.[doi:10.3877/cma.j.issn.1674-3253.2023.04.025]
　[J].,2023,17(04):423.[doi:10.3877/cma.j.issn.1674-3253.2023.04.025]

备注/Memo

备注/Memo:
基金项目：广东省自然科学基金（2016A030313605）
通讯作者：郑少斌，Email：uro@fimmu.com；陈彤，Email：nfyy144 @163.com
更新日期/Last Update: 2017-08-25